Codexis, Inc. CDXS
We take great care to ensure that the data presented and summarized in this overview for CODEXIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDXS
View all-
Opaleye Management Inc. Boston, MA8.84MShares$24.6 Million8.29% of portfolio
-
Casdin Capital, LLC New York, NY8.1MShares$22.5 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.79MShares$18.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.46MShares$12.4 Million0.0% of portfolio
-
Telemark Asset Management, LLC Boston, MA3MShares$8.34 Million1.53% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.84MShares$7.9 Million0.68% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.4MShares$6.67 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$5.16 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.81MShares$5.04 Million0.0% of portfolio
-
Baillie Gifford & CO1.69MShares$4.71 Million0.01% of portfolio
Latest Institutional Activity in CDXS
Top Purchases
Top Sells
About CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Insider Transactions at CDXS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
85,000
+0.92%
|
$170,000
$2.54 P/Share
|
|
Mar 06
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.09%
|
$200,000
$2.61 P/Share
|
|
Mar 05
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.11%
|
$20,000
$2.69 P/Share
|
|
Mar 04
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
55,000
+0.61%
|
$110,000
$2.64 P/Share
|
|
Mar 03
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
47,351
+0.53%
|
$94,702
$2.81 P/Share
|
|
Feb 28
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
147,649
+1.64%
|
$295,298
$2.99 P/Share
|
|
Feb 12
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
15,000
+0.17%
|
$60,000
$4.0 P/Share
|
|
Feb 11
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
12,500
+0.14%
|
$50,000
$4.11 P/Share
|
|
Feb 10
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,500
+0.26%
|
$90,000
$4.18 P/Share
|
|
Feb 05
2025
|
Kevin Norrett Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,875
+13.16%
|
-
|
|
Feb 05
2025
|
Stephen George Dilly |
BUY
Grant, award, or other acquisition
|
Direct |
88,750
+11.65%
|
-
|
|
Feb 05
2025
|
Georgia Erbez Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,875
+25.9%
|
-
|
|
Feb 05
2025
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,875
+13.28%
|
-
|
|
Jan 31
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
45,000
+0.52%
|
$180,000
$4.29 P/Share
|
|
Jan 30
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.23%
|
$80,000
$4.49 P/Share
|
|
Jan 14
2025
|
Christos Richards |
BUY
Grant, award, or other acquisition
|
Direct |
44,150
+50.0%
|
-
|
|
Dec 31
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.12%
|
$40,000
$4.66 P/Share
|
|
Dec 30
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
35,000
+0.41%
|
$140,000
$4.7 P/Share
|
|
Nov 07
2024
|
Raymond De Vre |
BUY
Grant, award, or other acquisition
|
Direct |
47,846
+50.0%
|
-
|
|
Oct 25
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.29%
|
$50,000
$2.91 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.88M shares |
|---|---|
| Grant, award, or other acquisition | 572K shares |